Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
18 févr. 2020 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
19 déc. 2019 08h25 HE
|
Selecta Biosciences, Inc.
– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212
19 déc. 2019 08h15 HE
|
Selecta Biosciences, Inc.
– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) --...
Selecta Biosciences Announces $70 Million Private Placement
19 déc. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors
21 nov. 2019 08h00 HE
|
Selecta Biosciences, Inc.
– Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™...
Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference
12 nov. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
11 nov. 2019 09h00 HE
|
Selecta Biosciences, Inc.
– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – –...
Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
08 nov. 2019 08h00 HE
|
Selecta Biosciences, Inc.
- Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic...
Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
01 nov. 2019 08h09 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
24 oct. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...